Cargando…

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis

Background: Tacrolimus (TAC) effectively induces remission in refractory ulcerative colitis (UC). However, TAC therapy usually lasts for 3 months. Although azathioprine (AZA) is often used in maintenance therapy, the relapse rate remains high. Herein, we evaluated the efficacy of adalimumab (ADA) fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Numa, Keijiro, Kakimoto, Kazuki, Tanaka, Yasuyoshi, Mizuta, Noboru, Kinoshita, Naohiko, Nakazawa, Kei, Koshiba, Ryoji, Hirata, Yuki, Ota, Kazuhiro, Miyazaki, Takako, Nakamura, Shiro, Higuchi, Kazuhide, Nishikawa, Hiroki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607785/ https://www.ncbi.nlm.nih.gov/pubmed/37892837 http://dx.doi.org/10.3390/jcm12206699

Ejemplares similares

Risk Factors for Nephrotoxicity due to Tacrolimus Therapy for Ulcerative Colitis
por: Nakata, Satoshi, et al.
Publicado: (2022)

Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis
por: Tatsumi, Yoshihiro, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis
por: Tawa, Hideki, et al.
Publicado: (2022)

Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis
por: Kinoshita, Naohiko, et al.
Publicado: (2022)

Fr581 EVALUATION OF SEQUENTIAL CHANGES IN THE INTESTINAL FLORA OF PATIENTS TAKING LOW-DOSE ASPIRIN AND A PROTON-PUMP INHIBITOR
por: Hirata, Yuki, et al.
Publicado: (2021)

Relationship between Chemotherapy-Induced Diarrhea and Intestinal Microbiome Composition
por: Kawasaki, Yuka, et al.
Publicado: (2023)

The Differential Diagnosis of Colorectal Polyps Using Colon Capsule Endoscopy
por: Nakazawa, Kei, et al.
Publicado: (2021)

Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance
por: Nishikawa, Hiroki, et al.
Publicado: (2021)

The Relationship between the SARC-F Score and the Controlling Nutritional Status Score in Gastrointestinal Diseases
por: Ikegami, Takako, et al.
Publicado: (2022)

Comparison of SARC-F Score among Gastrointestinal Diseases
por: Ushiro, Kosuke, et al.
Publicado: (2021)

Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers
por: Matsui, Masahiro, et al.
Publicado: (2021)

The Relevance in the Neutrophil to Lymphocyte Ratio and the SARC-F Score in Gastrointestinal Diseases
por: Yamasaki, Eiki, et al.
Publicado: (2022)

Grip Strength in Patients with Gastrointestinal Diseases
por: Asaishi, Ken, et al.
Publicado: (2022)

The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients
por: Hiraoka, Sakiko, et al.
Publicado: (2015)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
por: Kimura, Noriko, et al.
Publicado: (2019)

Preventive effect of ecabet sodium on low-dose aspirin-induced small intestinal mucosal injury: a randomized, double-blind, pilot study
por: Ota, Kazuhiro, et al.
Publicado: (2019)

Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis
por: Nishida, Yu, et al.
Publicado: (2019)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
por: Carlsen, Arne, et al.
Publicado: (2019)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022)

Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study): A Multicenter Prospective Clinical Trial
por: Kakimoto, Kazuki, et al.
Publicado: (2020)

Prognostic Impact of Ectopic Fat Deposition within Psoas Muscle in Stage IV Gastric Cancer Patients Undergoing Systemic Chemotherapy
por: Ikegami, Takako, et al.
Publicado: (2022)

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study
por: Eng, Grith P., et al.
Publicado: (2015)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
por: Wu, Kai-Chun, et al.
Publicado: (2016)

Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
por: Wong, Rochelle, et al.
Publicado: (2023)

RETRACTED ARTICLE: Novel Therapeutic Approach Using Drug-loaded Adipose-derived Stem Cells for Pancreatic Cancer
por: Aoki, Masahiko, et al.
Publicado: (2019)

Retraction Note: Novel Therapeutic Approach Using Drug-loaded Adipose-derived Stem Cells for Pancreatic Cancer
por: Aoki, Masahiko, et al.
Publicado: (2021)

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study
por: Hirata, Shintaro, et al.
Publicado: (2013)

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis
por: Sakurai, Toshiharu, et al.
Publicado: (2020)

Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease
por: Lucafò, Marianna, et al.
Publicado: (2021)

Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study
por: Ito, Ayumi, et al.
Publicado: (2016)

Successful remission of ulcerative colitis flare-up during pregnancy with adsorptive granulomonocytapheresis plus tacrolimus
por: Shibuya, Tomoyoshi, et al.
Publicado: (2018)

High exposure to tacrolimus is associated with spontaneous remission of recurrent membranous nephropathy after kidney transplantation
por: Buxeda, Anna, et al.
Publicado: (2023)

Effect of egualen sodium hydrate on small-intestinal mucosal damage induced by low-dose aspirin: a prospective randomized clinical trial
por: Iguchi, Munetaka, et al.
Publicado: (2018)

Augmented O-GlcNAcylation alleviates inflammation-mediated colon carcinogenesis via suppression of acute inflammation
por: Hirata, Yoshimasa, et al.
Publicado: (2018)

Safety, efficacy, and maneuverability of a self-propelled capsule endoscope for observation of the human gastrointestinal tract
por: Ota, Kazuhiro, et al.
Publicado: (2021)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
por: Sieper, Joachim, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gqdht0prq6gh6v0tugj8p3kp2e